Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

Overview of attention for article published in The Journal of Headache and Pain, January 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

twitter: 6 X users

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 51 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Data Suggest Efficacy of Erenumab in OnabotulinumtoxinA-Resistant Migraineurs

AJMC, 26 Jan 2021

Treatment with erenumab led to improvements in pain, medication use, and quality of life in onabotulinumtoxinA (BoNTA)-resistant…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.